Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title Pharmacokinetics and Immunodynamics of Immune stimulating chemotherapeutic nanoparticles for TB
Description The purpose of this study is to develop a new treatment for tuberculosis (TB). It is expected that direct participation in this study will be during participants' blood draw.

Participants will be asked to participate in a blood draw that will take about 15-30 minutes.

Study visits will be in downtown Buffalo

If you're interested in this study, please contact the study contact listed below.
Objective (CSR# 171180369595) Cells that fight infection (marcophage) will be isolated from whole blood of healthy donors. All studies are in vitro laboratory studies looking at the effects of nanoparticles on primary macrophage. Primary macrophage are preferred over the use of macrophage cell-lines as they more accurately recapitulate physiology. Macrophage will be incubated with free drug or nanoparticles (concentration: drug MIC) over several half-life increments of each drug.
Supernatant and cell lysate will be collected. Samples will be analyzed by UPLC-MS for intracellular drug concentration; by ELISA for concentrations of cytokines secreted; by ROS assay for reactive oxygen and reactive nitrogen species generation, and; using a calcium detection kit to determine Ca2+ release.

Keywords: Tuberculosis (TB), Macrophages
Principal Investigator REYNOLDS, JESSICA
Age Group Adult
Drugs Involved
Clinical Trials.gov
Status Open
Key Eligibility Healthy Adult
Ages 18-65
Willing to serve as a control in the study
Disease Group Healthy Volunteers; Infectious Diseases
Treatment
Contact JESSICA REYNOLDS
716-888-4777
jlr8@buffalo.edu